Tuesday, September 28, 2021

Antipsychotics Increase Risk of Dementia; New Research Illuminates Why

6
In JAMA psychiatry, researchers outline new theories connecting antipsychotic use in people with schizophrenia and increased dementia risk.

An FDA Whistleblower’s Documents: Commerce, Corruption, and Death

167
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.

Randomized Controlled Trial Confirms That Antipsychotics Damage the Brain

90
A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

Tapered Antipsychotic Withdrawal Mitigates Risk of Psychotic Symptoms

15
Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.

Psychiatry Defends Its Antipsychotics: A Case Study of Institutional Corruption

152
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.

The Charade of New Drug Approvals for Schizophrenia

91
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

Sudden Antipsychotic Withdrawal—Not Low Dose—Leads to Relapse

12
A new article in Lancet Psychiatry debunks past studies claiming that those on low doses of antipsychotics are more likely to relapse.

A Short History of Tardive Dyskinesia: 65 Years of Drug-Induced Brain Damage That Rolls...

92
Psychiatry has long turned a blind eye to the full scope of harm associated with TD. New TD drugs "work" by further impairing brain function.

The BBC, Harrow, and a Public Left in the Dark

73
The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

Recovery Rate Six Times Higher For Those Who Stop Antipsychotics Within Two Years

61
People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.

Do Antipsychotics Protect Against Early Death? A Review of the Evidence

75
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

Vitamin B6 Effective in Reducing Antipsychotic Induced Akathisia

8
A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.

The Latest “Breakthrough Therapy”: Expensive New Drugs for Tardive Dyskinesia

67
The increased prescribing of antipsychotics, which frequently cause a brain injury that manifests as tardive dyskinesia, has provided pharmaceutical companies with a lucrative new market opportunity.

Anticholinergic Medications Linked to Cognitive Impairment in Schizophrenia

3
Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.

Antipsychotic Adherence Research Overlooks Key Information

17
Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.

Very Slow Taper Best for Antipsychotic Discontinuation

12
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
Question mark inside a maze in the shape of human head.

New Study: The Clinical High Risk for Psychosis (CHR-P) Model Is Flawed

3
The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.

For People “At Risk for Psychosis,” Antipsychotics Associated with Worse Outcomes

26
Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

Review Explores First-Person Experiences of People Taking Antipsychotics

56
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

The Case Against Antipsychotics

130
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
digital antipsychotic

The Rise of the Digital Asylum

92
The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

Anticholinergic Psychiatric Drugs Linked to a 50% Increase in Dementia

17
People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.

Largest Survey of Antipsychotic Experiences Reveals Negative Results

13
A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

Antipsychotic Trials Show Increasing Placebo Response and Declining Drug Response

8
A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.
Doctor and patient

Barriers to Shared Decision Making in the Prescription of Antipsychotics

26
Researchers push for a renewed focus on true shared decision-making for patients diagnosed with psychosis.

Follow Us

19,639FansLike
23,715FollowersFollow
0SubscribersSubscribe